IL4 and acute myeloid leukemia: More recent findings substantiate those earlier observations and show that IL-4 has the potential to inhibit survival of AML cell lines as well as patient-derived AML cells, irrespective of their cytogenetic status and French-American-British (FAB) subtype, without affecting normal HSPCs.